Phase 2
Completed N=255
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
Metastatic Breastcancer
Source: ClinicalTrials.gov NCT01746225 ↗
Enrolled (actual)
255
Serious AEs
59.2%
Results posted
Mar 2020
Primary outcomePrimary: Progression-free Survival — 7.9; 9.0; 8.5 months — p=0.12
Summary
Longer first line chemotherapy duration has recently been associated with a modest, but significant improvement in overall survival and a clinically meaningful and statistically significant improvement in progression-free survival, in metastatic breast cancer patients. Prolonging chemotherapy until disease progression, however, must be weighed against the detrimental effects of continuous chemotherapy delivery. The SNAP trial seeks to improve the tolerability of prolonged chemotherapy administration strategy by studying alternative treatment schedules, while preserving and possibly improving treatment efficacy in this disease setting.
The availability of a new nanoparticle albumin-bound taxane, nab-Paclitaxel (Abraxane®), represents an opportunity to test this hypothesis. Nab-Paclitaxel has been developed in an attempt to reduce the toxicity associated with standard taxane administration (caused by the use of chemical solvents) while increasing antitumor efficacy.
The SNAP randomized phase II trial evaluates three schedules of nab-Paclitaxel as prolonged chemotherapy administration strategy. Each of three arms will be compared to a historical reference of seven-month median progression-free survival (PFS) based on the most recent trial with docetaxel as control arm to determine whether any of the three arms are worthy of further investigation.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Progression-free Survival |
7.9; 9.0; 8.5 | 0.12 |
| SECONDARY Feasibility of Treatment: Number of Participants Completed Treatment According to the Protocol for at Least 24 Weeks |
40; 43; 44 | — |
| SECONDARY Disease Control: Overall Response of Stable Disease for a Duration of ≥24 Weeks |
54; 59; 52 | — |
| SECONDARY Best Overall Response |
5; 6; 4; 34; 41; 35 | — |
| SECONDARY Overall Survival |
25.8; 26.2; 25.5 | — |
| SECONDARY Changes in Physical Well-being (Change From Day 1 of Cycle 4 to Day 1 of Cycle 6) |
-2; 1; 4 | — |
Eligibility Criteria
Inclusion Criteria
- Histologically or cytologically confirmed HER2-negative metastatic (stage IV) breast cancer.
- Measurable or non-measurable, but radiologically evaluable, disease according to RECIST 1.1 criteria.
- Female aged 18 years or older.
- Life expectancy > 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
- Either ER-positive or ER-negative disease. Patients with ER-positive disease must be endocrine resistant, defined as having failed at least one prior endocrine therapy for breast cancer, or must be candidates for first-line chemotherapy.
- If previously treated with a taxane or anthracycline in the neoadjuvant or adjuvant setting, the period from end of treatment to disease recurrence must have been > 12 months (> 365 days).
- Radiation therapy, if given and regardless of site, must be completed at least 2 weeks prior to randomization.
- Normal hematologic status.
- Normal renal function.
- Normal liver function.
- Normal cardiac function.
- Women of childbearing potential: documented negative pregnancy test within 2 weeks prior to randomization, and acceptable birth control during the duration of the trial therapy and for a period of 6 months following the last administration of study drug.
- Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to randomization.
- Completed baseline Quality of Life Form.
- The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.
- Availability of an formalin fixed paraffin embedded (FFPE) block from the primary tumor (breast lesion) for submission to central pathology review and for translational research.
- Written consent to pathology material submission, signed and dated by the patient and the Investigator prior to randomization.
Exclusion Criteria
- Any prior chemotherapy for metastatic breast cancer.
- Presence of central nervous system (CNS) metastasis.
- Peripheral neuropathy grade 2 or higher (CTCAE version 4).
- Significant uncontrolled cardiac disease (i.e. unstable angina, recent myocardial infarction within prior 6 months), patients classified as having a New York Heart Association (NYHA) class III or IV congestive heart failure.
- Pregnant or lactating.
- Prior history of non-breast malignancy (except for adequately controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the bladder).
- Any concurrent condition which in the Investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol.
- Contraindications or known hypersensitivity to the study medication or excipients.
- The use of any anti-cancer investigational agents within 30 days prior to expected start of trial treatment.
- Inability or unwillingness to abide by the study protocol or cooperate fully with the Investigator.
Data sourced from ClinicalTrials.gov (NCT01746225). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.